Optiray (Ioversol)

Ioversol, the active ingredient in Optiray, is an iodinated contrast agent presented as a solution for injection for intraarterial and intravenous use. It provides radiopaque contrast that enhances visualization of vascular and tissue structures during diagnostic imaging procedures. Optiray is used in a variety of contrast‑enhanced radiographic studies to improve image quality and diagnostic accuracy.

GNH USA supplies Optiray as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Optiray is an iodinated contrast agent used in diagnostic imaging procedures to improve visualization of anatomical structures.

- Vascular imaging (angiography): enhances visualization of blood vessels during angiographic studies. - Computed tomography (CT) imaging: provides contrast enhancement for clearer CT images of organs and tissues. - Urography: improves delineation of urinary tract structures during contrast‑enhanced examinations. - Contrast‑enhanced radiographic procedures: facilitates better imaging of various body parts in radiography.

Adverse reactions may occur following administration of iodinated contrast agents.

Common Side Effects: - Warmth or flushing sensation during injection. - Metallic taste in the mouth. - Nausea or mild vomiting. - Headache or dizziness. - Mild injection site pain or bruising. - Transient increase in serum creatinine.

Serious or Rare Side Effects: - Severe allergic reactions, including anaphylaxis. - Acute kidney injury, especially in patients with pre‑existing renal impairment. - Cardiovascular collapse or severe hypotension. - Seizures or neurologic disturbances. - Pulmonary edema or respiratory distress.

Prior to using Optiray, certain precautions should be observed to minimize risk.

- Renal function: assess baseline kidney function and consider hydration in at‑risk patients. - Allergy history: evaluate for prior reactions to iodinated contrast agents. - Thyroid status: monitor patients with hyperthyroidism or thyroid disorders. - Metformin therapy: suspend metformin in patients with reduced renal function before and after administration. - Pregnancy and lactation: use only if clearly necessary after risk‑benefit assessment. - Store at ambient temperature: keep in original container, protect from light and moisture.

Ioversol may interact with other medications, requiring careful management.

Major Interactions (Avoid): - Metformin: risk of lactic acidosis in patients with renal impairment; consider temporary discontinuation. - Nephrotoxic drugs (e.g., aminoglycosides, NSAIDs): may exacerbate renal toxicity when combined with contrast. - Thyroid hormones: iodinated contrast can affect thyroid function tests and hormone levels.

Moderate Interactions (Monitor Closely): - Diuretics: may increase risk of dehydration and renal injury. - ACE inhibitors or ARBs: monitor blood pressure and renal function. - Other contrast agents: avoid sequential administration without adequate interval. - Beta‑blockers: may mask signs of contrast‑induced hypertension.